Ibandronate works by binding to hydroxyapatite in bone, inhibiting osteoclast-mediated bone resorption. This process is particularly beneficial in cancer patients who suffer from bone metastases, a common complication in cancers such as breast cancer and prostate cancer. By reducing bone turnover, ibandronate helps stabilize the bone microenvironment.
